Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Jefferies

Right-Wing Protectionism is Costing Texas

Laws banning the state from doing business with banks that are dubbed anti-fossil fuel or anti-gun could cost 100s of millions in interest.

Texas Observer

Apple Lures China iPhone Customers With Deep Discounts But Sales Stutter Amid Domestic Weakness: Report

Apple Inc.’s (NASDAQ: AAPL) iPhone 14 sales in China are taking a hit as consumers tighten their purse strings amid e

Benzinga

UK political crisis: Pound extends gain as focus turns to future UK leadership

LONDON: The pound extended gains after Liz Truss announced she was resigning as UK prime minister, capping weeks of speculation on the future of her premiership since her initial fiscal policy drove markets into turmoil.

The Times of India

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The war for your teeth

Millions of dollars in legal bills and aggressive marketing have piled up.

Axios

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022

Upgrades See all analyst ratings upgrades.

Benzinga

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022

Upgrades

Benzinga

A new work anxiety: Will I be penalized for working from home?

In the "new normal" of the hybrid workplace, are remote and in-person workers going to be treated equally? It's a matter of hot debate right now.

WEKU

Climate change, scarcity chip away at degrowth taboo

Degrowth - the idea that a finite planet cannot sustain ever-increasing consumption - is about the closest you can get to a heresy in economics, where growth is widely held as the best route to prosperity.

Reuters

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022

Upgrades

Benzinga

Jefferies Maintains Hold Rating for Douglas Emmett: Here's What You Need To Know

Jefferies has decided to maintain its Hold rating of Douglas Emmett (NYSE:DEI) and lower its price target from $31.00 to $24.00. Shares of Douglas Emmett are trading down 1.04% over the last 24 hours, at $22.32 per share. A move to $24.00 would account for a 7.5% increase from the…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Upgrades

Benzinga

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price. Jefferies, J.P. Morgan, SVB Securities, and Stifel are acting as joint…

Benzinga

Microsoft Whale Trades For June 17

Someone with a lot of money to spend has taken a bearish stance on Microsoft (NASDAQ:MSFT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Jefferies Maintains Buy Rating for Outbrain: Here's What You Need To Know

Jefferies has decided to maintain its Buy rating of Outbrain (NASDAQ:OB) and lower its price target from $9.00 to $8.00. Shares of Outbrain are trading down 14.48% over the last 24 hours, at $4.75 per share. A move to $8.00 would account for a 68.24% increase from the current share…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

Upgrades

Benzinga

Tapestry — Owner Of Fashion Brand Coach — Is A "Structural Pandemic Winner," Jefferies Says In Upgrade: What Else Impressed This Analyst?

Tapestry Inc (NYSE: TPR) has been through a culture change focusing on data-driven results, which should continue to drive progress, according to Jefferies.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.